Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
Telegram Restored on Apple App Store After Temporary Removal 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal 
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum 
NEW YORK, April 03, 2018 -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focusing on the development of innovative cancer therapies, today announced that the Company has filed its annual report on Form 20-F for the fiscal year ended December 31, 2017 with the U.S. Securities and Exchange Commission on April 03, 2018. The annual report can be accessed on the Company’s investor relations website at http://ir.beyondspringpharma.com.
The Company will provide a hard copy of its annual report containing its audited consolidated financial statements, free of charge, to its shareholders upon request. Requests should be directed to Investor Relations, BeyondSpring Inc., 28 Liberty Street, 39th Floor, New York, NY 10005 USA.
About Plinabulin
Studies on Plinabulin's method of action indicate that Plinabulin activates GEF-H1, a guanine nucleotide exchange factor. GEF-H1 activates downstream transduction pathways leading to the activation of the protein c-Jun. Activated c-Jun enters the nucleus of dendritic cells to upregulate immune-related genes, which contributes to the up-regulation of a series of genes leading to dendritic cell maturation, T-cell activation and other effects that prevent neutropenia.
About BeyondSpring
BeyondSpring is a global, clinical-stage biopharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with University of Washington in de novo drug discovery using ubiquitination platform. BeyondSpring’s lead asset, Plinabulin, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and two Phase 2/3 clinical programs in the prevention of chemotherapy-induced neutropenia (CIN). BeyondSpring has a seasoned management team with many years of experience bringing drugs to the global market.
Contact:
Media Relations:
Caitlin Kasunich / Amy Singh
KCSA Strategic Communications
212.896.1241 / 212.896.1207
[email protected] / [email protected]
Investor Relations:
Laura Perry / Joseph Rayne
Argot Partners
212.600.1902
[email protected]
